GILD — Gilead Sciences, Inc.

The market is looking straight through the accounting loss. On 2026-08-04 Gilead reported Q2 2026 total revenue of $7.803B (+10.2% YoY vs. $7.081B in Q2 2025), raised full-year base-business guidance to $29.8–30.1B and lifted its HIV growth outlook to 9–10%, and followed it with FDA approval of once-daily Bixlenvo on 2026-08-27 plus a first-line metastatic TNBC expansion for Trodelvy and PrEP crossing $1B in a quarter for the first time. The tape agrees: even after the -4.82% week into 2026-09-13, GILD is +14.44% over three months and sits 4.08% above its 50-day and 6.67% above its 200-day (as of 2026-09-13). Sell-side posture is lopsided — 38 Buys/Strong Buys against 1 Sell, consensus price target $150 (recent average $147.33) — but note the stock is already within ~4% of that target, which is why the recent week gave some back.

The core trend is one of genuine acceleration, obscured by two charge quarters. Revenue YoY: Q1 2025 -0.3%, Q2 2025 +1.8%, Q3 2025 +3.0%, Q4 2025 +4.7%, Q1 2026 +4.4%, Q2 2026 +10.2% — a clear inflection, not a blip, and management has guided FY26 to ~$30–30.7B with HIV in the high single digits. Sequential revenue dipped to $6.960B in Q1 2026 (normal seasonality) then snapped back to $7.803B in Q2 2026, the strongest top-line quarter in the three-year window. Reported income is distorted: Q1 2024 carried a -$4.322B operating loss (EPS -$3.34) and Q2 2026 carried a -$10.394B operating loss (EPS -$8.45) on the ~$11.2B IPR&D charge; every clean quarter in between ran 34–43% adjusted operating margins (Q3 2025 was the best at 42.8%, $3.327B on $7.769B). Free cash flow is the cleanest signal: TTM FCF of $12.965B (Q3 2025 $3.961B + Q4 2025 $3.121B + Q1 2026 $2.427B + Q2 2026 $3.456B) versus $9.369B a year earlier — up ~38% YoY, with the Q2 2025 trough ($0.720B) now well behind it. Structural story: HIV/PrEP is compounding, oncology is the swing factor, and cell therapy is decelerating (-14% YoY in Q2 2026 on Tecartus pressure). One flag the score's own notes pick up: stockholders' equity fell ~50% between 2026-03-31 ($23.515B) and 2026-06-30 ($11.828B), which is the acquisitions plus the write-off, not organic deterioration — but it does break any equity-based ratio comparison across that point.

On reported figures it looks insane; on normalized figures it's fair, not cheap. As of 2026-09-13 the screen shows P/E TTM -55.3x, P/B 15.1x, P/S 5.86x, EV/EBITDA 317x — every one of those is a casualty of the one-time IPR&D charge and the halved equity base, and none should be used. The usable math: TTM revenue $30.456B against a $178.4B market cap is 5.86x sales versus a 5-year own-history average of 4.04x, so on sales it screens rich relative to its own past. But normalized EPS — roughly 37% adjusted operating margin on ~$30.7B forward revenue, less ~$1.0B interest, ~20% tax, on ~1.242B shares — is about $7.00, putting the stock at ~20.5x normalized earnings. Trailing FCF yield is 7.3% and EV/FCF is roughly 15x on ~$200B EV. For a 0.35-beta defensive large-cap with an 80% gross margin, 20.3% ROIC, a 2.59% dividend and now-accelerating revenue, ~20x normalized and ~15x EV/FCF is a reasonable, unremarkable price — the analyst consensus of $147–150 (low $123, high $175) essentially agrees.

This is the classic 'don't screen it on the headline multiple' setup. GAAP EPS for Q2 2026 was -$8.45 and the next-FY consensus EPS average is -$0.441, which means any P/E-based screen, quant factor model, or PEG calculation will misread Gilead for at least two to three more quarters — the reported loss is an acquisition artifact, not a demand or pricing problem. The market has already re-rated on the right numbers (adjusted EPS, FCF, base-business guidance), which is why the stock is +14.44% over three months despite a -$10.5B net-loss quarter. The flip side is that at ~20x normalized earnings and within ~4% of the consensus target, the easy money on the guidance raise has already been made; the next leg depends on HIV share defense (Biktarvy >52% US share) and on the pipeline converting — anito-cel's 2026-12-23 PDUFA being the biggest single swing. A beat-and-raise on Q3 is roughly priced in; a pipeline delay is not.

Range-bound with an intact intermediate uptrend, short-term cooling. As of 2026-09-13, RSI(14) sat at 50.49 — dead neutral, no overbought/oversold signal — with the stock at $143.72, which is 1.73% below its 20-day (~$146), 4.08% above its 50-day (~$138) and 6.67% above its 200-day (~$135). Returns as of that date: +5.78% over one month, +14.44% over three months, -0.88% over six months, -4.82% over one week. Translation: the multi-month trend is up and the moving averages are stacked bullishly, but the recent week was a sharp give-back from near the 52-week high of $157.29, and the stock is now trading below its short-term average. Entry-timing implication: no urgency to chase — the ~$138 50-day and ~$135 200-day are the obvious support shelf, and a pullback into that zone is a materially better risk/reward than $144 with the consensus target at $150. A decisive break below ~$135 would break the uptrend and change the read.

• Rates and defensive rotation: with a 0.35 beta, a 2.59% dividend yield and ~$13B of trailing free cash flow, GILD is a classic bond-proxy-adjacent large-cap biopharma that benefits if rates normalize and capital rotates toward defensive-but-growing cash generators.
• Drug pricing and IRA/regulatory scrutiny: global pricing pressure on specialty drugs remains a permanent background tax on the HIV and oncology franchises, partially offset by Gilead's positioning in high-unmet-need areas.
• Capital deployment and balance-sheet strain: the Arcellx, Tubulis and Ouro buyouts plus an announced $32B domestic R&D/manufacturing plan through 2030 have pushed debt-to-equity to 2.22x and long-term debt to $23.832B while cash fell to $3.179B as of 2026-06-30 — less dry powder for the next deal.
• Competitive dynamics in cell therapy and long-acting HIV: Q2 2026 cell therapy sales fell 14% YoY on Tecartus pressure, while oral weekly and long-acting injectable HIV competition intensifies — Gilead leads the latter but is no longer alone.
• Sector rotation and biotech risk appetite: large-cap biopharma is currently favored over small/mid-cap biotech for its cash flows, which supports the multiple but also means GILD is a funding source if risk appetite rotates harder into speculative biotech.

• Anito-cel PDUFA action date of 2026-12-23 in multiple myeloma (from the Arcellx acquisition) — the single largest pipeline optionality event, and a test of whether the ~$11.2B of IPR&D spend was well allocated.
• Continued HIV/PrEP momentum: PrEP already crossed $1B in a quarter, Biktarvy holds >52% US HIV treatment share, and Bixlenvo (approved 2026-08-27) ramps into the same franchise.
• Data readouts for weekly oral HIV combinations (islatravir/lenacapavir) heading into late 2026/2027, which would extend the franchise's patent runway.
• Trodelvy first-line metastatic triple-negative breast cancer launch in the US and EU following regulatory expansion.
• Management commentary at the Morgan Stanley Global Healthcare Conference in mid-September 2026, and any further FY26 guidance raise on the Q3 print.
• Negative-side catalyst to watch: another round of business development bringing a fresh IPR&D charge, which would keep GAAP EPS negative and equity depressed.

• Concentration and patent cliff: the HIV franchise is the profit engine, and Biktarvy's eventual loss of exclusivity later this decade is the single biggest structural threat to the cash flow that funds everything else.
• Serial acquisition risk: stockholders' equity fell from $23.515B to $11.828B in one quarter, debt-to-equity is now 2.219x and cash is down to $3.179B — if anito-cel or the weekly-HIV assets disappoint, a meaningful chunk of that $11.2B write-off becomes permanent value destruction.
• Pipeline decay already visible: cell therapy revenue fell 14% YoY in Q2 2026, evidence that Gilead's non-HIV portfolio can erode rather than compound.
• Accounting optics keeping a lid on the multiple: with next-FY consensus EPS of -$0.441 and reported operating margin of -4.9%, screen-based and quant buyers are structurally excluded for several more quarters.
• Regulatory and pricing pressure on specialty drugs, particularly in oncology where Trodelvy's expansion invites scrutiny.
• Valuation risk from the price move: +14.44% in three months to within ~4% of the $150 consensus target means a Q3 miss or anito-cel delay has little cushion.

The underlying business is meaningfully healthier than the reported financials suggest — Q2 2026 revenue growth accelerated to +10.2% YoY, trailing free cash flow is $13.0B and up ~38% YoY, gross margin is 79.6%, ROIC is 20.3%, and the HIV/PrEP franchise is compounding with a 2.59% dividend attached, all at a 0.35 beta. But at $143.72 you're paying ~20x normalized EPS and ~15x EV/FCF for that, which is fair rather than cheap, and the stock has already run 14.44% in three months to sit within spitting distance of the $150 consensus target. This is a quality defensive compounder to own or accumulate on pullbacks toward the ~$138 50-day, not a mispriced bargain to back up the truck on — and anyone who screens it on the -55x trailing P/E is going to get the story exactly backwards.

Blended two approaches as of 2026-09-13: (1) normalized-earnings multiple — ~37% adjusted operating margin on ~$30.7B forward revenue, less ~$1.0B interest and ~20% tax, on ~1.242B shares gives ~$7.00 normalized (ex-IPR&D) EPS, and 21x that (a supportable multiple for a 0.35-beta, 2.6%-yielding large-cap with high-single-digit revenue growth and 20% ROIC) is ~$147; and (2) cash-flow multiple — TTM FCF of $12.965B at 16.5x EV/FCF gives ~$214B EV, less ~$22.7B net debt, divided by 1.242B shares is ~$154. Averaging the two and adding a modest premium for anito-cel pipeline optionality yields $152.